Charles River Laboratories International EBITDA 2011-2026 | CRL

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Charles River Laboratories International

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
428 M	589 M	931 M	955 M	855 M	668 M	549 M	493 M	419 M	279 M	301 M	274 M	248 M	247 M	204 M	-205 M	260 M	-365 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
955 M	-365 M	396 M

Quarterly EBITDA Charles River Laboratories International

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1	2010-Q3	2010-Q2
187 M	219 M	220 M	195 M	-	206 M	238 M	211 M	-	230 M	243 M	245 M	-	226 M	264 M	224 M	-	224 M	206 M	185 M	129 M	192 M	134 M	152 M	109 M	145 M	129 M	115 M	102 M	128 M	120 M	101 M	62.8 M	108 M	113 M	102 M	69.1 M	92.9 M	90.4 M	76.1 M	52.3 M	79.3 M	78.9 M	65.4 M	40.8 M	72.2 M	75.3 M	59.8 M	24.6 M	108 M	83.6 M	62.8 M	-	98.3 M	89.3 M	63.7 M	-	101 M	96.4 M	63.5 M	77.1 M	76.1 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
264 M	24.6 M	130 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Diagnostics research industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Enzo Biochem ENZ	-11.1 M	-	-8.98 %	$ 14.8 K	USA
Centogene N.V. CNTG	-46 M	-	-6.23 %	$ 30.6 M	Germany
Heska Corporation HSKA	-6.33 M	-	-	$ 1.31 B	USA
DermTech DMTK	-104 M	-	-11.32 %	$ 2.94 M	USA
Quest Diagnostics Incorporated DGX	2.13 B	$ 203.06	-0.38 %	$ 22.5 B	USA
Celcuity CELC	-172 M	$ 88.55	-1.05 %	$ 4.14 B	USA
Akumin AKU	70.1 M	-	-17.87 %	$ 25.9 M	Canada
Co-Diagnostics CODX	-49.1 M	$ 4.29	-8.72 %	$ 5.71 M	USA
Fulgent Genetics FLGT	-67 M	$ 18.68	-0.53 %	$ 575 M	USA
Castle Biosciences CSTL	-2.04 M	$ 20.7	-1.48 %	$ 600 M	USA
Aspira Women's Health AWH	-7.8 M	-	-6.19 %	$ 10.5 M	USA
Accelerate Diagnostics AXDX	-33.9 M	-	-61.36 %	$ 2.46 M	USA
Biocept BIOC	-30.3 M	-	-13.05 %	$ 7.29 M	USA
ICON Public Limited Company ICLR	826 M	$ 146.18	-2.49 %	$ 11.5 B	Irlanda
Oxford Immunotec Global PLC OXFD	-3.26 M	-	-	$ 562 M	Britain
Guardant Health GH	-398 M	$ 131.62	0.55 %	$ 16.5 B	USA
CareDx, Inc CDNA	-15.8 M	$ 22.97	-2.92 %	$ 1.22 B	USA
Chembio Diagnostics CEMI	-21.1 M	-	0.22 %	$ 16.8 M	USA
Check-Cap Ltd. CHEK	-2.37 M	-	-	$ 9.42 M	Israel
Interpace Biosciences IDXG	4.51 M	$ 1.6	-3.03 %	$ 7.08 M	USA
Illumina ILMN	1.08 B	$ 160.97	-3.15 %	$ 25 B	USA
HTG Molecular Diagnostics HTGM	-20.2 M	-	-20.0 %	$ 1.06 M	USA
Global Cord Blood Corporation CO	652 M	-	-	$ 399 M	China
National Research Corporation NRC	30.2 M	$ 18.79	-	$ 421 M	USA
Fluidigm Corporation FLDM	-35.1 M	-	1.08 %	$ 308 M	USA
Natera NTRA	-268 M	$ 212.07	-3.27 %	$ 29 B	USA
Genetic Technologies Limited GENE	-6 M	-	-	$ 7.1 B	Australia
Genetron Holdings Limited GTH	-702 M	-	0.12 %	$ 80.1 M	China
Pacific Biosciences of California PACB	-541 M	$ 1.31	-2.96 %	$ 393 M	USA
Lantheus Holdings LNTH	381 M	$ 104.52	0.19 %	$ 7.05 B	USA
PRA Health Sciences, Inc. PRAH	416 M	-	-	$ 10.7 B	USA
Medpace Holdings MEDP	562 M	$ 467.34	-1.63 %	$ 13.5 B	USA
Exact Sciences Corporation EXAS	-81.4 M	-	-	$ 19.8 B	USA
Mettler-Toledo International MTD	51.1 M	$ 1 131.49	-0.86 %	$ 23.3 B	Schweiz
NeoGenomics NEO	-79.8 M	$ 11.15	-2.79 %	$ 1.43 B	USA
Myriad Genetics MYGN	-334 M	$ 4.33	-6.48 %	$ 401 M	USA
Personalis PSNL	-78 M	$ 9.59	1.8 %	$ 856 M	USA
Koninklijke Philips N.V. PHG	2.55 B	$ 26.46	1.34 %	$ 25.1 B	Niderland
Twist Bioscience Corporation TWST	-111 M	$ 76.17	2.86 %	$ 4.56 B	USA
Senseonics Holdings SENS	-66.8 M	$ 7.18	-2.05 %	$ 300 M	USA
QIAGEN N.V. QGEN	660 M	-	-	$ 10.6 B	Niderland
Soleno Therapeutics SLNO	11.4 M	-	-	$ 2.69 B	USA
Biomerica BMRA	-5.05 M	$ 2.05	-1.91 %	$ 4.71 M	USA
Laboratory Corporation of America Holdings LH	2.07 B	$ 266.16	0.34 %	$ 22.1 B	USA
Thermo Fisher Scientific TMO	8.8 B	$ 469.34	-1.33 %	$ 177 B	USA
Trinity Biotech plc TRIB	-21.2 M	$ 0.65	-3.7 %	$ 233 M	Irlanda
Motus GI Holdings MOTS	-11.5 M	-	-34.28 %	$ 263 K	Israel
Neogen Corporation NEOG	-942 M	$ 9.1	-1.57 %	$ 1.97 B	USA
Invitae Corporation NVTA	47.2 M	-	-	$ 21.2 M	USA